Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nitargal is a pharmaceutical substance developed by UNITEHPROM at the Belarusian State University (BSU). It is a coordination complex consisting of silver ions and the amino acid L-arginine. The substance is primarily utilized as an active pharmaceutical ingredient (API) for the production of medicinal products with dual therapeutic profiles. Due to the presence of silver, it exhibits broad-spectrum antimicrobial and antiseptic properties, making it effective for wound healing and the treatment of purulent-inflammatory conditions. Additionally, Nitargal serves as a nitric oxide (NO) donor; the arginine component acts as a precursor for NO production, which induces vasodilation. This mechanism has led to its investigation and application in cardiovascular medicine for the treatment of conditions such as angina pectoris and hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nitargal.